MedPath

Xadcera Biopharmaceutical(Suzhou)Co.,Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

A Study of DM002 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Ovarian Neoplasms
Prostatic Neoplasms
Endometrial Neoplasms
Colorectal Neoplasms
Solid Carcinoma
Interventions
First Posted Date
2024-12-27
Last Posted Date
2025-04-17
Lead Sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Target Recruit Count
160
Registration Number
NCT06751329
Locations
🇺🇸

The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

🇦🇺

Cancer Care Wollongong, Wollongong, New South Wales, Australia

A Study of DM001 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Breast Neoplasms
Solid Carcinoma
Interventions
First Posted Date
2024-06-26
Last Posted Date
2025-04-17
Lead Sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Target Recruit Count
128
Registration Number
NCT06475937
Locations
🇺🇸

Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States

🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇦🇺

Icon Cancer Centre South Brisbane, South Brisbane, Queensland, Australia

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.